Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040425 (tonsillitis)
 1,594 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Infectious pneumonias are inflammations of the lung that can be localized in the alveoli or interstitial tissue or both. The pathogenic agent is usually airborne; more rarely it is hematogenous. Important distinctions are between bacterial and nonbacterial forms, between diseases acquired outside and inside hospitals, and between patients who are basically healthy and those with a previous illness. Pneumococci continue to be the dominant pathogens outside hospitals. In hospitals, gram-negative, anaerobic, and fungal pathogens are more often found. Usually, purulent chronic bronchitis or an acute exacerbation of chronic bronchitis is based on a prior viral infection or an impairment of bacterial clearance mechanisms of the respiratory tract. The dominant pathogens are Haemophilus influenzae and pneumococci. Worldwide, viral infections of the upper respiratory tract have great epidemiological significance. With 12 different groups of viruses and more than 150 serotypes, there can be many causes of symptoms of rhinitis, tonsillitis, pharyngitis, laryngitis, and tracheitis as well as bronchitis.
 ...
PMID:Respiratory infection: the disease. 407 65

We studied BRL 25000, (amoxicillin trihydrate and potassium clavulanate a beta-lactamase inhibitor in ratio of 2: 1), in the otorhinolaryngological field in terms of its basic and clinical utility. Pharmacokinetics The distribution of BRL 25000 in mucous membrane of maxillary sinus and retaining liquid of maxillary sinus after administration of 1 tablet (375 mg) was favorable and the good transitional properties were obtained. It was similar to chephems. Clinical results BRL 25000 was administered to 26 patients (6 cases with otitis media, 9 cases with tonsillitis, 2 cases with sinusitis, 1 case with laryngitis, 5 cases with pharyngitis, 1 case with epipharyngitis and 2 cases with pharyngolaryngitis). The overall clinical effective response was obtained in 88.5% of patients. Bacteriological effects BRL 25000 was effective against amoxicillin-resistant S. aureus and K. rhinoscleromatis. Side effects No adverse reactions were seen.
 ...
PMID:[Experimental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) in the field of otorhinolaryngology]. 655 6

Acute respiratory tract infections represent the major cause of morbidity in younger age groups. Most of these infections involve the upper respiratory tract. The frequency of respiratory tract infections vary not only with age, but also with season of the year and the epidemiological situation. Surveys of the incidence and aetiology of these infections must therefore cover large populations during relatively long periods of time. In the developed countries, the mortality in respiratory tract infections in patients below the age of 60 years is low, while it increases markedly in elderly patients, mainly due to involvement of the lower respiratory tract. Aetiologically, viral infections dominate but bacterial pathogens often cause pharyngitis/tonsillitis, otitis media and sinusitis. In longstanding cough in children, Branhamella catarrhalis has been found to be a pathogen of probably high significance. Other factors increasing the clinical importance of colonisation of the upper respiratory tract with potentially pathogenic bacterial species, are various immune defects, especially reduced IgA production, and granulocytopenia. In the latter case, Gram-negative bacteria seem to be more pathogenic than Gram-positive ones. The clinical differentiation between viral and bacterial upper respiratory tract infections is difficult and sometimes not possible. However, based on the knowledge that acute tracheitis, laryngitis and common cold are normally caused by viral agents, it seems reasonable not to use antibiotics for those patients.
 ...
PMID:Clinical aspects on bacterial infections in the upper respiratory tract. 658 Jul 30

Eight years after the first study published in this Journal (1985, 7: 533), we compared antibiotic treatment of respiratory infections at the Pediatric Emergency Department of the Children's Hospital in Trieste. All patients with pneumonia and pertussis received antibiotics, compared to 87% of otitis, 55% of pharyngo-tonsillitis, 4% of upper respiratory infections (U.R.I.); neither asthma nor laryngitis were treated with antibiotics. In particular, only 13% of otitis were treated by symptomatics, the others with amoxicillin (51%), amoxicillin + clavulanic acid (18%), cefaclor (12%), trimethoprim-sulphamethoxazole (5%), josamycin (1%). 45% of pharyngo-tonsillitis was treated with symptomatics, 32% with macrolides and 10% with penicillin; rarer treatment comprehended amoxicillin, amoxicillin + clavulanic acid (10%) and cefaclor (3%). Pneumonia was treated with amoxicillin or cefaclor (30% both), with amoxicillin + clavulanic acid (10%) or with macrolides (30%), the last in provision of mycoplasmal etiology. Antibiotic treatment of U.R.I. is progressively decreased from 79% in 1974 to 13% in 1983 and to 4% in 1991. Antibiotic treatment in our Department was appropriate in the majority of patients, with almost all bacterial form treated with first choice, cheaper antibiotic. A negative, limited trend was detected for pharyngo-tonsillitis: first choice antibiotics passed from 82% in 1983 to 76% in 1991. Another positive factor is due to the homogeneous manners of the doctors working at the Emergency Department, belonging to two different teams (Emergency and Clinical Departments), probably with the use of common clinical protocols.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[The antibiotic treatment of respiratory infections in a pediatric emergency room]. 807 88

We investigated clinical and bacteriological effects of cefetamet pivoxil (CEMT-PI) in community-acquired respiratory tract infections and obtained the following findings. That method was approximately equal to that of investigation in 1994. 1. Of the 431 respiratory tract infection cases that were treated with CEMT-PI according to a same protocol at a total of 41 institutions in Tokyo, Kanagawa-ken, Saitama-ken and Chiba-ken from January to the beginning of March 1996. Outpatients accounted for 98.1% of the subjects. Regarding genders to patients, slightly more females (52.6%) than males were included. Diagnoses given to these patients included pharyngo-laryngitis (53.5%), tonsillitis (20.4%) and acute bronchitis (19.1%). 2. We investigated clinical efficacy rates (the ratio of those excellent + good) classified by diseases. The improvement rates of pharyngo-laryngitis, tonsillitis and acute bronchitis were more than 85.0%. Other cases were small in number. That of chronic bronchitis-acute increasing change for the worse was 66.7%, pneumonia was 50.0% and bronchiectasis infection was 16.7%. It was not studied that clinical efficacy rates among those who were treated with 1 CEMT-PI tablet twice and among those who were given 2 tablets twice were significant level. 3. For the bacteriological study, a written material describing the method of collecting specimens, storage and transport in detail was distributed to the above mentioned institutions. The isolation and identification of suspected causative bacteria, determination of minimum inhibitory concentrations (MICs) and investigation of beta-lactamase production were conducted all together at section of studies, Tokyo Clinical Research Center. Suspected causative bacteria were detected from 274 (63.6%) cases. They included 88 strains of Haemophilus influenzae, 47 strains of Streptococcus pneumoniae, 42 strains of Streptococcus pyogenes, 20 strains of Moraxella subgenus Branhamella catarrhalis and 17 strains of Klebsiella pneumoniae subsp. pneumoniae. Suspected causative bacteria classified by diseases were S. pyogenes (tonsillitis), S. pneumoniae (acute bronchitis and secondary infection of chronic respiratory infection) and H. influenzae (pharyngo-laryngitis), and the detection frequency of those was high. The clinical efficacies (the ratio of improvement) classified by suspected causative bacteria were 84.4% against organism that was indicating CEMT and were 69.2% against organism that was not indicating CEMT.
 ...
PMID:[Clinical and bacteriological effects of cefetamet pivoxil against community-acquired respiratory tract infections. Part II]. 939 36

As the main target of influenza viral aggression, the respiratory tract is subject to easier bacterial infection superimposition. The researchers from Les Laboratoires Servier--France, managed to isolate a substance--fusafungine--from the microspore of the fungus Fusarium lateritium, which demonstrates unique anti-inflammatory and antibiotic action, and is the active ingredient of Bioparox Spray, an inhalant. The principal indications of Bioparox Spray for treatment of respiratory tract infections fall within the range from the sinuses to the finest alveolar duct, namely: rhinitis, sinusitis, tonsillitis, pharyngitis, laryngitis, tracheitis and bronchitis. In terms of technology Bioparox is unique due to the fact that 90% of the aerosol particles are less than one micron large, while generally the particles needed for penetration through the alveolar duct should be less than three microns. Due to such micronization, after inhalation Bioparox Spray reaches from the sinuses to the finest bronchial branches. Bioparox Spray possesses sound and broad antibiotic spectrum of action on the most common causative agents of respiratory infections, and more over, it acts upon Candida albicans, unlike the remaining broad-spectrum antibiotics. Bioparox Spray also has an independent anti-inflammatory effect by blocking the inflammation mediators: Bioparox Spray inhibits the synthesis of free radicals and the action of IL1 and TNF as pro-inflammatory factors, and it potentiates the action of IL2 and interferon-gamma which are anti-inflammatory factors. By its dual antibiotic and anti-inflammatory action Bioparox Spray is an excellent alternative to the conventional antibiotic therapy.
 ...
PMID:[An alternative to conventional antibiotic therapy in respiratory infections--Bioparox Spray]. 1098 75

Between 1 April 1996 and 30 June 1997, 1003 ear, nose and throat (ENT) outpatients and 340 inpatients diagnosed as having pulmonary tuberculosis were analysed for ENT manifestations of tuberculosis to determine the relationship to sputum positivity, whether any high risk factors exist for the ENT manifestations as compared to other pulmonary tuberculosis patients, and the response to anti-tubercular treatment. The commonest ENT manifestation was found to be laryngitis (seven cases), which was more common in pulmonary tuberculosis patients (five out of seven), all except one of whom were sputum negative. All of these patients were defaulters from anti-tuberculosis treatment or relapse cases, and vocal cords were the commonest site of involvement. One case of tuberculous tonsillitis and one case of tuberculous mastoiditis were also noted. The practical implications of an awareness of ENT tuberculosis is a benefit of anti-tubercular therapy and hence conservative management usually suffices.
 ...
PMID:Epidemiological considerations and clinical features of ENT tuberculosis. 1148 87

A number of 150 samples were prelevated from respiratory tract secretions of 88 patients with respiratory infections and three healthy subjects; 162 haemophilus strains were isolated, identified and studied and the following results were obtained: H. parainfluenzae was isolated from tonsillitis and laryngitis--over 70%, bronchitis--58% and pharyngitis--56.6%; H. influenzae was isolated from pharyngitis--26.4%, bronchitis--16.1% and tonsillitis--13.6% cases; H. parahaemolyticus from bronchitis--19.3%, tonsillitis--13.6% and laryngitis. H. paraphrophilus was isolated (6.8%) from pharyngitis, tonsillitis, sinusitis, bronchitis and pulmonary abscess and H. paraphrohaemolyticus was isolated--4.5% from pharyngitis, synusitis, bronchitis and pulmonary sarcoidosis. Most of the isolates belonged to biotype II H. influenzae and biotypes II, I, III H. parainfluenzae. Haemophils were 100% sensitive to Ofloxacin and resistant to Cro--13.5%, Do--17.9%, C and Caz--22.2%, Aml--24.6%, Rd--40.7%, Amp--41.9% and Te--63.5%; varying according to the haemophilus species. H. influenzae was resistant to Do--14.2%, Caz and C--21.4%, H. parainfluenzae was resistant to Cro--11%, Do--22%, whilst H. parahaemolyticus was resistant to Do--9% and to Aml, Caz and Cro--13.6%. Haemophils isolated from sputum showed a resistance higher by 12-34% and 6-17% than those isolated from other specimens, such as pharyngeal exudate, where the resistance to rifadin was lower by 10%. beta-lactamases were present in 27.7% of the strains: H. parainfluenzae--36%, H. paraphrohaemolyticus--25%, H. influenzae--17.8% and H. parahaemolyticus--15.7%; in strains from sputum--34.2%, pharyngeal exudate--28.8% and from other specimens--6.6%. No correlations were noticed between the biotype and the clinical manifestation or the resistance to the antibiotic, a higher frequency of beta-lactamase production being reported in H. influenzae biotype V and H. parainfluenzae biotypes II and IV.
 ...
PMID:Frequency and distribution per species, biotypes, resistance to antibiotics and beta-lactamase production of the haemophils isolated from patients with respiratory diseases. 1184 30

Streptococcus constellatus, S. intermedius, and S. anginosus, the 3 species of the S. milleri group, form part of the normal flora commonly found in the mouth, throat, and gastrointestinal and genital tracts. This group has become known as an important pathogen in infections and abscesses, but data on the anatomical distribution of these species is lacking in relation to clinical significance. We obtained 275 strains of the S. milleri group from different departments at our hospital over the last 3 years, including 54 strains from dental surgery, 47 from internal medicine, 44 from otolaryngology (head and neck), 43 from surgery, 32 from gynecology, 17 from urology, 16 from dermatology, 11 from brain surgery, 6 from pediatrics, 3 from orthopedics, and 2 from opthalmology. The 44 strains from head and neck were found in 42 patients,--23 with primary infection and 19 with secondary infection induced by cancer treatments. The primary infection group included 4 deep neck abscesses, 1 peritonsillar abscess, 5 tonsillitis, 4 paranasal sinusitis, 3 congenital aural fistula infections, 2 dental infections, 2 paranasal sinus cysts, 1 supprative parotitis, and 1 postoperative wound infection. The secondary infection group included 7 postoperative wound infections, 3 postoperative pulmonary infections, 3 laryngitis and pharyngitis, 3 terminal pneumonias, and 3 infections of the local recurrence site. The S. milleri group was the only isolated organism in 13 cases (56.5%) of primary infection and in 5 (26.3%) of secondary infection. Among other organisms from the primary infection group, no so-called major pathogens were found. Antimicrobial susceptibility tests of the S. milleri group showed that 50% were resistant to CCL and 33% to CTM. ABPC, CPDX, and CFDN were also found to be less sensitive, although no resistant strains were detected. To adequately culture the S. milleri group, incubation in air containing carbon dioxide or in an anaerobic atmosphere is required, and differentiation of the 3 requires biochemical reactivity tests. Since not all facilities use identical techniques in routine bacteriological examination, a considerable number of the S. milleri group could be missed in unknown species of alpha-,beta-, and gamma-streptococci and culture-negative cases. With antibiotics now being used widely, normal flora such as the S. milleri group may have become an important pathogen in head and neck infections due to an imbalance between organisms and host defense.
 ...
PMID:[Clinical relevance of the Streptococcus milleri group in head and neck infections]. 1185 84

Air pollution in all its forms, including sulfur dioxide, ozone, fine particles, carbon monoxide and nitrogen oxides, has resulted in human deaths and diseases worldwide. This article reports on the human suffering caused by air pollution in terms of mortality and morbidity. Based on interviews with scientists, health experts and victims, it is noted that the cities of Thailand, Mexico, Japan, Poland, the Czech Republic, Romania, and the US have the highest levels of air pollution. In these areas people suffer from respiratory illnesses such as pharyngitis, sinusitis, laryngitis, tonsillitis, bronchitis, asthma, flu, and loss of lung function. A most alarming finding indicates that residents of Los Angeles exposed to ozone pollution have double the risk of cancer compared to residents of cleaner cities. Aggravating this situation is the fact that governments often opt to sacrifice human health and lives when forced to choose between protecting the public and shielding industry from pollution regulations.
 ...
PMID:Poisons in the air. 1232 55


<< Previous 1 2 3 Next >>